诺华公司一款降胆固醇药物在临床试验中失败,Royalty Pharma股价下跌

路透中文
Sep 09
BUZZ-<a href="https://laohu8.com/S/NVS">诺华</a>公司一款降胆固醇药物在临床试验中失败,Royalty Pharma股价下跌

9月8日 - ** Royalty Pharma(RPRX.O)股价在午后交易中下跌6%,至60.14美元

** RPRX从学术实验室和生物技术公司购买未来药物的专利使用费

** 瑞士制药商诺华(Novartis) NOVN.S 旗下降胆固醇药物佩拉卡森(pelacarsen)在一项备受关注的研究中未能通过 (link)

** RPRX表示,其与诺华(NOVN)合作伙伴Ionis IONS.O 达成的5亿美元融资协议,旨在通过另一款药物Spinraza稳定且可预见的专利使用费,以及pelacarsen带来的潜在收益,来控制风险

** 尽管佩拉卡森(pelacarsen)试验失败,RPRX仍预计将收回全部投资并获得适度的正回报

** “我们此前曾预计,到2032年,佩拉卡森和安进公司(Amgen)的奥尔帕西兰(olpasiran)的终端市场总销售额将达到16亿美元,特许权使用费为8000万美元(占RPRX收入的1%)。虽然错失了这次机会,但增长前景基本未变。”——Royalty Pharma

** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”

** 计入本交易日涨幅,该股今年以来累计上涨54.7%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10